Patients with Heart Failure During and After Inpatient Cardiac Rehabilitation

Figures & data

Table 1 Patient Characteristics

Variables	N=200
Sociodemographic data
Age (years)	64.7 ± 11.9
Female sex (%)	24.1
Male sex (%)	75.9
Weight (kg)	86.2 ± 17.1
BMI (kg/m^2)	29 ± 5.2
Length of inpatient rehabilitation (days)	21.7 ± 3.5
Patient history/comorbidities
Active smoking (%)	29.1
Hypertension (%)	79.9
Diabetes (%)	41.7
COPD (%)	8
Dyslipoproteinemia (%)	69.8
Renal insufficiency (%)	16.1
Atrial fibrillation (%)	23.1
Coronary heart disease (%)	45.7
Acute myocardial infarction (%)	66.3
Pulmonary embolism (%)	4.5
Heart Failure groups
HFrEF (%)	13.5
HFmrEF (%)	33
HFpEF (%)	53.5
Cost bearer
German pension insurance (%)	48.2
Health insurance (%)	51.8
Graduation
No graduation (%)	1.5
Apprenticeship (%)	86.7
Graduate (%)	11.8
Employment
Employed (%)	33.8
Unemployed (%)	9
Retired (%)	56.8

Note: Categorial variables are presented in percent; continuous normally distributed variables as mean ± standard deviation at admission.

Abbreviations: HFrEF, highly reduced ejection fraction; HFmrEF, midrange reduced ejection fraction; HFpEF, preserved ejection fraction.

Figure 1 Development of vital parameters between admission and discharge.

Figure 2 NYHA-classes during study course.

Figure 3 (A) HDS-D, anxiety score. (B) HADS-D, depression score.

Figure 4 (A) SF-12: Physical summation scale. (B) SF-12: Psychologic summation scale.

Table 2 Drug Treatment During Study Course

Drug, %	Admission	Discharge	After 3 Months	After 12 Months
Ca-antagonists	24.1	33.8	28.8	29.7
Beta-blockers	88.4	88.4	87.3	87.9
Ivabradine	1.5	6.6	1.8	2.4
Amiodaron	4.5	2.5	3.0	3.0
ACE inhibitors	52.8	45.2	42.4	37.6
ARBs	28.1	39.4	36.9	40.0
Sacubitril/valsartan	1.5	2.5	5.4	5.5
MRA	27.5	27.9	26.8	24.4
Statins	75.4	83.3	79.4	76.4
Aspirin	71.9	67.7	66.1	63.6
P2Y12 inhibitors	56.3	56.6	50.0	21.2
OACs	31.2	34.3	31.5	30.9
Insulin	2.5	14.1	13.3	10.9
OADs	21.1	24.7	23.0	23.6

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; OAK, oral anticoagulation; OAD, oral antidiabetics; MRA, mineralocorticoid receptor antagonist.

Figure 5 Heart failure medication during study course.

Figure 6 Hospitalizations.

Figure 7 Heart failure caused rehospitalization and death during study course.